<DOC>
	<DOCNO>NCT00089856</DOCNO>
	<brief_summary>The purpose study compare duration survival GVAX® immunotherapy prostate cancer chemotherapy treatment patient prostate cancer long respond hormone therapy , document metastasis , treat chemotherapy past .</brief_summary>
	<brief_title>GVAX® Vaccine Prostate Cancer v Docetaxel &amp; Prednisone Patients With Metastatic Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Confirmed diagnosis clinical history consistent adenocarcinoma prostate Metastatic prostate cancer deem unresponsive refractory hormone therapy Detectable metastases Any Gleason score ECOG performance status 02 Prior treatment chemotherapy Prior Immunotherapy Prior treatment gene therapy Significant cancer relate pain</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Hormone-refractory</keyword>
	<keyword>GVAX</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Allogeneic cell</keyword>
	<keyword>Advanced Prostate Cancer</keyword>
</DOC>